Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04790643
Other study ID # 35831220.8.0000.5402
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date May 3, 2021
Est. completion date August 2022

Study information

Verified date July 2021
Source Universidade Estadual Paulista Júlio de Mesquita Filho
Contact Luiz Carlos Marques Vanderlei, PhD
Phone +55183229-5819
Email lcm.vanderlei@unesp.br
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This research project has as objective the elaboration and analysis of a new cardiac risk stratification protocol based on clinical and physical variables to predict the occurrence of signs and symptoms during a cardiac rehabilitation program. To this aim, the study will be developed in three stages. The first stage consists of a prospective longitudinal observational study, in which participants of exercise-based cardiac rehabilitation will undergo a physiotherapy evaluation in terms of physical and clinical aspects. After this initial assessment, participants will be followed for 2 months of rehabilitation, when the occurrence of signs and symptoms (chest pain, fatigue, dizziness, arrhythmias, and other minor events) during exercise will be recorded. Based on the data from the initial assessment and the occurrence of signs and symptoms a new cardiac risk stratification protocol will be developed. The second stage of this project consists of another prospective longitudinal observational study in which a new sample of individuals attending cardiac rehabilitation programs will be assessed and stratified for the risk of the occurrence of signs and symptoms during exercise by the new protocol developed. After the risk stratification, this sample will be followed for 2 months and the occurrence of signs and symptoms will be recorded. With this data, the reproducibility and efficacy of the protocol will be evaluated. The third stage of this project consists of a cross-sectional observational study, in which a new sample of participants will be evaluated by two independent physiotherapists for clinical and physical variables, and based on these data will be stratified by the new protocol by the same evaluators independently. After these procedures, the protocol´s agreement between evaluators will be analyzed.


Recruitment information / eligibility

Status Recruiting
Enrollment 130
Est. completion date August 2022
Est. primary completion date April 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Main medical diagnostic of any cardiovascular disease and/or presence of cardiovascular risk factors - Be participating in exercise-based cardiac rehabilitation Exclusion Criteria: - Orthopedic and/or neurologic conditions that preclude the realization of any of the physical and clinical evaluations - Do not complete 24 cardiac rehabilitation sessions during the follow-up period

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Exercise-based cardiac rehabilitation program (Stage 1)
In Stage 1 the volunteers will perform 24 sessions of exercise-based cardiac rehabilitation. The rehabilitation session is composed of the following activities: I. Initial rest (where the vital signs are evaluated); II. Warming-up (composed of 15 minutes of stretching and global exercises); III. Aerobic exercise (composed of 30 minutes of treadmill or cycle ergometer exercise, the intensity established varies from 40 to 70% of the heart rate reserve for those diagnosed with cardiovascular diseases and from 60 to 80% of the heart rate reserve for those with only cardiac risk factors); IV. Cooldown (composed of 5 minutes of slow walking).
Exercise-based cardiac rehabilitation program (Stage 2)
In Stage 2, the volunteers will perform 24 sessions of exercise-based cardiac rehabilitation. The rehabilitation session is composed of the following activities: I. Initial rest; II. Warming-up; III. Aerobic exercise (these three activities are the same as stage 1); IV. Resistance training (composed of 15 minutes of individualized resistance exercises); V. Cooldown.

Locations

Country Name City State
Brazil Universidade Estadual Paulista Júlio de Mesquita Filho Presidente Prudente São Paulo

Sponsors (1)

Lead Sponsor Collaborator
Universidade Estadual Paulista Júlio de Mesquita Filho

Country where clinical trial is conducted

Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Other Reproducibility of the risk stratification protocol to predict the signs and symptoms occurrence The agreement between the risk class and the number of signs and symptoms that occurred will be calculated using the Kappa intraclass correlation coefficient. Through study completion, an average of 2 years
Other Efficacy of the risk stratification protocol to predict the signs and symptoms occurrence The effectiveness of the protocol in predicting the occurrence of signs and symptoms will be assessed by analyzing the ROC curve, by measuring sensitivity, specificity and area under the curve (AUC). Through study completion, an average of 2 years
Other Agreement between evaluators Reliability between evaluators will be assessed using the percentage of agreement and disagreement and the Kappa index. Through study completion, an average of 2 years
Primary Signs and symptoms The occurrence rate of signs and symptoms will be evaluated during the exercise performed in cardiac rehabilitation programs. The signs and symptoms considered are: arrhythmia, the elevation of systolic and diastolic blood pressure, tachypnea, pallor, angina, cramp, muscle pain, fatigue, and nausea. Baseline assessment
Primary Resting heart rate Evaluated through a heart rate monitor during a resting period of 20 minutes. The mean heart rate obtained between the 5th and 20th minutes will be considered. Baseline assessment
Primary Blood pressure Evaluated indirectly by an experienced physiotherapist using a stethoscope and a sphygmomanometer. The blood pressure will be evaluated three times after a resting period of 15 minutes. The mean value of the last 2 measures will be considered. Baseline assessment
Primary Maximum inspiratory pressure Evaluated through a manovacuometer. This assessment will be evaluated three times and the value considered will be the mean of all measures. Baseline assessment
Primary Maximum expiratory pressure Evaluated through a manovacuometer. This assessment will be evaluated three times and the value considered will be the mean of all measures. Baseline assessment
Primary Peak expiratory flow Evaluated through the spirometric examination performed by an experienced physiotherapist. Baseline assessment
Primary Forced expiratory volume in the first second Evaluated through the spirometric examination performed by an experienced physiotherapist. Baseline assessment
Primary Forced vital capacity Evaluated through the spirometric examination performed by an experienced physiotherapist. Baseline assessment
Primary Cardiac autonomic modulation - RMSSD index The data for this evaluation will be collected using a heart rate monitor that registers the heart rate beat by beat and provides information regarding the RR intervals. To obtain the RR intervals time series, the volunteer will rest for 30 minutes in spontaneous breathing. Will be considered 1000 consecutive RR intervals recorded between the 5th and 30th minutes of rest. The RMSSD index corresponds to the root-mean square of differences between adjacent normal RR intervals in a time interval, expressed in milliseconds. Baseline assessment
Primary Cardiac autonomic modulation - SDNN index The data for this evaluation will be collected using a heart rate monitor that registers the heart rate beat by beat and provides information regarding the RR intervals. To obtain the RR intervals time series, the volunteer will rest for 30 minutes in spontaneous breathing. Will be considered 1000 consecutive RR intervals recorded between the 5th and 30th minutes of rest. The SDNN index corresponds to the standard deviation of all normal RR intervals recorded in a time interval, expressed in milliseconds. Baseline assessment
Primary Cardiac autonomic modulation - LF index (ms²) The data for this evaluation will be collected using a heart rate monitor that registers the heart rate beat by beat and provides information regarding the RR intervals. To obtain the RR intervals time series, the volunteer will rest for 30 minutes in spontaneous breathing. Will be considered 1000 consecutive RR intervals recorded between the 5th and 30th minutes of rest. The LF index is the low-frequency component of the oscillatory components of heart rate variability, and ranges from 0.04 to 0.15 Hz. Baseline assessment
Primary Cardiac autonomic modulation - HF index (ms²) The data for this evaluation will be collected using a heart rate monitor that registers the heart rate beat by beat and provides information regarding the RR intervals. To obtain the RR intervals time series, the volunteer will rest for 30 minutes in spontaneous breathing. Will be considered 1000 consecutive RR intervals recorded between the 5th and 30th minutes of rest. The HF index is the high-frequency component of the oscillatory components of heart rate variability, and ranges from 0.15 to 0.4 Hz. Baseline assessment
Primary Cardiac autonomic modulation - LF index (nu) The LF index expressed in normalizefd units (nu) is obtained by dividing the power in milliseconds by the total power spectrum, minus the very low frequency component and multiplied by 100. Baseline assessment
Primary Cardiac autonomic modulation - HF index (nu) The HF index expressed in normalizefd units (nu) is obtained by dividing the power in milliseconds by the total power spectrum, minus the very low frequency component and multiplied by 100. Baseline assessment
Primary Cardiac autonomic modulation - LF/HF ratio This index is obtained by dividing the LF (ms²) value by the HF (ms²) value. Baseline assessment
Primary Cardiac autonomic modulation - SD1 index The data for this evaluation will be collected using a heart rate monitor that registers the heart rate beat by beat and provides information regarding the RR intervals. To obtain the RR intervals time series, the volunteer will rest for 30 minutes in spontaneous breathing. Will be considered 1000 consecutive RR intervals recorded between the 5th and 30th minutes of rest. The SD1 index corresponds to the dispersion of points perpendicular to the line of identity of the ellipse obtained from the Poincaré plot. Expressed in milliseconds. Baseline assessment
Primary Cardiac autonomic modulation - SD2 index The data for this evaluation will be collected using a heart rate monitor that registers the heart rate beat by beat and provides information regarding the RR intervals. To obtain the RR intervals time series, the volunteer will rest for 30 minutes in spontaneous breathing. Will be considered 1000 consecutive RR intervals recorded between the 5th and 30th minutes of rest. The SD1 index corresponds to the dispersion of points along the line of identity of the ellipse obtained from the Poincaré plot. Expressed in milliseconds. Baseline assessment
Primary Cardiac autonomic modulation - SD1/SD2 ratio This index is obtained by dividing the SD1 value by the SD2 value. Baseline assessment
Primary Quadriceps muscle strength Evaluated through a digital dynamometer. The volunteer will perform three maximal isometric contractions of quadriceps with a duration of 5 seconds. The value considered will be the higher one among the three contractions. Baseline assessment
Primary Submaximal functional capacity Evaluated by the 6-minute walk test. The values considered will be the distance covered and the % of the predicted value reached. Baseline assessment
Primary Body mass index Calculated using the data of body mass assessed by a digital scale and height evaluated through a stadiometer. Baseline assessment
Primary Waist circumference Measured with an inelastic measuring tape at the lower abdominal perimeter. Three measurements will be taken and the average of the values obtained will be considered. Baseline assessment
Primary Abdominal circumference Measured with an inelastic measuring tape at the umbilical scar line. Three measurements will be taken and the average of the values obtained will be considered. Baseline assessment
Primary Hip circumference Measured with an inelastic measuring tape at the largest perimeter in the gluteal region. Three measurements will be taken and the average of the values obtained will be considered. Baseline assessment
Primary Arm circumference Measured with an inelastic measuring tape at the midpoint between the acromion and the olecranon with the upper limb relaxed. Three measurements will be taken and the average of the values obtained will be considered. Baseline assessment
Primary Calf circumference Measured with an inelastic measuring tape at the largest circumference in the region of the right calf with the lower limb relaxed without receiving weight. Three measurements will be taken and the average of the values obtained will be considered. Baseline assessment
Primary Basal metabolic rate (cal/day) Evaluated through a tetrapolar electrical bioimpedance examination. Baseline assessment
Primary Total body water (%) Evaluated through a tetrapolar electrical bioimpedance examination. Baseline assessment
Primary Total water in the lean mass (%) Evaluated through a tetrapolar electrical bioimpedance examination. Baseline assessment
Primary Resistance (Ohms) Evaluated through a tetrapolar electrical bioimpedance examination. Baseline assessment
Primary Reactance (Ohms) Evaluated through a tetrapolar electrical bioimpedance examination. Baseline assessment
Primary Body fat (%) Evaluated through a tetrapolar electrical bioimpedance examination. Baseline assessment
Primary Body fat (Kg) Evaluated through a tetrapolar electrical bioimpedance examination. Baseline assessment
Primary Total lean mass (Kg) Evaluated through a tetrapolar electrical bioimpedance examination. Baseline assessment
See also
  Status Clinical Trial Phase
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Recruiting NCT04417387 - The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
Not yet recruiting NCT06211361 - Cardiac Rehabilitation Program in Patients With Cardiovascular Disease N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT04514445 - The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
Enrolling by invitation NCT04253054 - Chinese Multi-provincial Cohort Study-Beijing Project
Completed NCT03273972 - INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers N/A
Completed NCT03680638 - The Effect of Antioxidants on Skin Blood Flow During Local Heating Phase 1
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Completed NCT04083846 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed) Phase 1
Completed NCT04083872 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting) Phase 1
Completed NCT03619148 - The Incidence of Respiratory Symptoms Associated With the Use of HFNO N/A
Completed NCT03466333 - Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia Phase 2
Completed NCT03693365 - Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
Completed NCT04082585 - Total Health Improvement Program Research Project
Completed NCT05132998 - Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors N/A
Completed NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)